MedTrace Logo

Angio-IMR and Cardiac MR-derived MVO in STEMI Patients

NCT04828681 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 324

Last updated 2025-03-14

No results posted yet for this study

Summary

Coronary microcirculatory dysfunction has been known to be prevalent even after successful revascularization of ST-segment elevation myocardial infarction (STEMI) patients. Microvascular obstruction (MVO) in cardiac magnetic resonance (CMR) is significant prognostic indicator in STEMI patients after primary percutaneous coronary intervention (PCI). Although current gold-standard method to assess microvascular damage or dysfunction in STEMI patients is CMR and assessment of MVO, previous study presented that index of microcirculatory resistance (IMR) in culprit vessel of STEMI patients showed significant association with the presence of MVO in CMR and the risk of cardiac death or heart failure admission. Nevertheless, the need for pressure-temperature sensor wire and hyperemic agents significantly limits adoption of IMR in daily practice.

Recent technical development enabled angiographic derivation of IMR without pressure wire, hyperemic agents, or thermodilution method. In this regard, the current study will evaluate the feasibility of functional angiography-derived IMR (angio-IMR) in the evaluation of MVO after successful primary PCI for STEMI.

Conditions

  • ST-segment Elevation Myocardial Infarction (STEMI)

Interventions

DIAGNOSTIC_TEST

Cardiac magnetic resonance imaging

Cardiac magnetic resonance imaging was performed 5.0 ± 5.8 days after the primary PCI. MVO, infarct size, and myocardial salvage index were quantitatively assessed in CMR.

Sponsors & Collaborators

  • RainMed Medical Group

    collaborator INDUSTRY

  • Shanghai Institute of Cardiovascular Diseases

    collaborator OTHER

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Joo Myung Lee, MD, MPH, PhD · Samsung Medical Center

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-24
Primary Completion
2021-12-31
Completion
2023-12-31

Countries

  • United States
  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04828681 on ClinicalTrials.gov